Ekso Bionics (NASDAQ:EKSO) CFO Sells $54,182.40 in Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CFO Jerome Wong sold 11,288 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $54,182.40. Following the completion of the sale, the chief financial officer directly owned 26,009 shares of the company’s stock, valued at $124,843.20. The trade was a 30.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Ekso Bionics Trading Up 9.2%

Shares of NASDAQ EKSO traded up $0.46 during midday trading on Wednesday, reaching $5.45. 86,719 shares of the stock were exchanged, compared to its average volume of 117,336. Ekso Bionics Holdings, Inc. has a 12 month low of $2.73 and a 12 month high of $14.97. The company has a market capitalization of $14.30 million, a price-to-earnings ratio of -0.96 and a beta of 1.08. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.66 and a quick ratio of 1.57. The business has a 50-day simple moving average of $4.77 and a two-hundred day simple moving average of $16.88.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Tuesday, October 28th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.45. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. The firm had revenue of $4.23 million for the quarter, compared to the consensus estimate of $4.16 million. As a group, equities research analysts expect that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $562.50.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC boosted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,042,382 shares of the company’s stock after purchasing an additional 316,733 shares during the period. Armistice Capital LLC owned 7.03% of Ekso Bionics worth $823,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.